

Article

Imidazo[1,2-a]pyridines susceptible to excited state intramolecular proton transfer: one-pot synthesis via an Ortoleva-King reaction

Anton J Stasyuk, Marzena Banasiewicz, Michal Ksawery Cyranski, and Daniel Tomasz Gryko

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jo300643w • Publication Date (Web): 04 Jun 2012

Downloaded from <http://pubs.acs.org> on June 5, 2012

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3
4 Imidazo[1,2-*a*]pyridines susceptible to excited state
5
6
7
8 intramolecular proton transfer: one-pot synthesis *via* an
9
10
11
12
13 Ortoleva-King reaction
14
15
16
17

18 *Anton J. Stasyuk,^{a,b} Marzena Banasiewicz,^c Michał K. Cyrański^{b*} and Daniel T. Gryko^{a,*}*
19

20
21 ^a Warsaw University of Technology, Faculty of Chemistry, Noakowskiego 3, 00-664 Warsaw, Poland.
22
23

24 ^b Warsaw University, Chemistry Department, Pasteura 1, 01-173 Warsaw, Poland
25
26

27
28 ^c Institute of Physics of the Polish Academy of Sciences, Al. Lotników 32/46, 02-668 Warsaw, Poland
29
30
31
32
33
34
35

36 **dtgryko@icho.edu.pl**

37
38 **chamis@chem.uw.edu.pl**
39

40
41 **RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required**
42
43 **according to the journal that you are submitting your paper to)**
44
45

46
47 ABSTRACT A short and efficient route to a broad range of imidazo[1,2-*a*]pyridines from 2-
48 aminopyridines and acetophenones is achieved by a tandem, one-pot process starting with an Ortoleva-
49 King reaction. Optimal conditions for the first step were established after examining various reaction
50 parameters (solvent, reagent ratios, and temperature). The conditions identified (1st step: neat, 2.3 equiv.
51 of 2-aminopyridine, 1.20 equiv of I₂, 4 h, 110 °C; 2nd step: NaOH_{aq}, 1 h, 100 °C) resulted in the
52
53
54
55
56
57
58
59
60

1 formation of imidazo[1,2-*a*]pyridines in 40-60% yields. The synthesis is compatible with various
2 functionalities (OH, NMe₂, Br, OMe). Products containing a 2-(2'-hydroxyphenyl) substituent undergo
3 excited state intramolecular proton transfer (ESIPT) in non-polar and polar-aprotic solvents. Although
4 ESIPT-type emission in non-polar solvents is weak the Stokes shifts are very high (11000 cm⁻¹). The
5 comparison of the properties of six ESIPT-capable imidazo[1,2-*a*]pyridines shows the influence of
6 various substituents on emission characteristics. All of them also display strong, solid-state emission in
7 blue-green-yellow region. 2-Aryl-imidazo[1,2-*a*]pyridines not capable of ESIPT emit in the blue region,
8 displaying high fluorescence quantum yield.
9
10
11
12
13
14
15
16
17
18
19
20

21 **Introduction:** The chemistry of imidazo[1,2-*a*]pyridines has been intensively investigated since
22 the beginning of the last century.¹ This area is still of great interest, mainly due to important biological
23 activity of these molecules. Imidazo[1,2-*a*]pyridines have significant importance in the pharmaceutical
24 industry owing to their interesting biological activity displayed over a broad range of therapeutic
25 classes; these molecules exhibit antiviral (anticytomegalo-zoster and antivaricella-zoster virus),² anti-
26 inflammatory,³ analgesic, antipyretic,⁴ antiulcer,⁵ and antibacterial⁶ properties. They are also β -amyloid
27 formation inhibitors,⁷ GABA and benzodiazepine receptor agonists,⁸ and cardiogenic agents.⁹ Drug
28 formulations containing imidazo[1,2-*a*]pyridine which are currently available on the market include
29 alpidem (anxiolytic),¹⁰ zolpidem (hypnotic),¹¹ and olprinone (PDE-3 inhibitor).¹²
30
31
32
33
34
35
36
37
38
39
40
41

42 Acuña and co-workers were the first to report that imidazo[1,2-*a*]pyridines possessing a 2-
43 hydroxyphenyl substituent at position 2 display excited-state intramolecular proton transfer (ESIPT).¹³
44 More recently, the photophysics of these compounds was studied by Araki and co-workers, who
45 discovered their strong solid-state emission.¹⁴ The design and characterization of compounds which
46 undergo ESIPT continues to engage the interest of scientists throughout the world¹⁵ because of the wide
47 applications of this phenomenon to such systems as laser dyes,¹⁶ fluorescence sensors¹⁷ and molecular
48 switches.¹⁸
49
50
51
52
53
54
55
56
57
58
59
60

1 A variety of synthetic methods have been reported for the preparation of substituted
2 imidazo[1,2-*a*]pyridines. The most important approaches embrace: (i) condensation of 2-aminopyridine
3 with α -halocarbonyl compounds,¹⁹ (ii) one-pot condensations of aldehydes, isonitriles, and 2-
4 aminopyridines,²⁰ and (iii) copper catalyzed three-component reactions of 2-aminopyridines, aldehydes
5 and alkynes.²¹ Other methods have also been developed within the last three decades.²²⁻²⁶ Although new
6 methods are continuously published,²⁷ the reaction of 2-aminopyridines with α -halogenoketones and α -
7 halogenoaldehydes is still the most popular. There are however two intrinsic limitations to this
8 methodology, namely the small variety of commercially available α -halogenocarbonyl compounds, and
9 their lachrymatory properties.

10 Herein we describe a new approach to the synthesis of substituted imidazo[1,2-*a*]pyridines,
11 based on the condensation of 2-aminopyridine with various aromatic ketones under Ortoleva-King
12 reaction conditions, followed by cyclization under the influence of base.

28 Results and discussion

29 We have observed that the structure of the intermediate product in the synthesis of imidazo[1,2-
30 *a*]pyridines from 2-aminopyridine and α -halocarbonyl compounds (i.e. the corresponding pyridinium
31 salt with a halogen counterion) represents the same type of compound as is formed in the Ortoleva-King
32 reaction. First Ortoleva,²⁸ and then King²⁹ demonstrated that pyridinium salts can often be conveniently
33 prepared in a direct synthesis by heating active methyl and methylene compounds with iodine in
34 pyridine. The yields of this elegant method are usually very good,³⁰ and a variety of heterocyclic bases
35 may be used instead of pyridine, including quinolines,³¹ isoquinolines, picolines³² and nicotinamide.³³
36 The reaction has been extended to include a variety other compounds containing active methyl and
37 methylene groups.

38 We envisioned that if 2-aminopyridine (**1**) could be used as a component in an Ortoleva-King
39 reaction with methylketones, the initially formed pyridinium salts would bear suitable functional groups
40 to form 2-substituted imidazo[1,2-*a*]pyridines in the second step. Needless to say, one must take into
41
42
43
44
45
46
47
48
49
50
51
52

1 consideration the numerous side reactions which may occur, including iodination of 2-aminopyridine.³⁴
2
3 Careful analysis of published data showed that the yields in Ortoleva-King reaction are usually very
4
5 good, but that separation of the iodide byproducts is sometimes accompanied by considerable losses.
6
7 These difficulties can be circumvented by precipitating the product from aqueous solution with sodium
8
9 perchlorate.³⁵ However, this route appeared unproductive to us, because it required additional time and
10
11 led to inevitable losses of the intermediate product.
12
13

14 It has been shown by Pearson³⁶ that the Ortoleva-King reaction can be represented as stepwise
15
16 mechanism. In this representation, the first step is α -proton detachment from the ketone with pyridine
17
18 serving as a base. This forms the corresponding conjugate base of the ketone, which is able to interact
19
20 with iodine giving α -iodomethylketone. The latter can react relatively easily with another molecule of
21
22 pyridine. Pearson has also shown that the rate of formation of β -ketoalkyl pyridinium iodides is much
23
24 faster than both the rate of reaction between ketone and heterocyclic amine base, and the rate of reaction
25
26 of the conjugate base with iodine. The limiting step of the whole process is the interaction of ketone
27
28 with amine. Therefore, we reasoned that when carrying out the reaction in excess of 2-aminopyridine it
29
30 might be possible to obtain reaction kinetics that were first order with respect to ketone and apparent-
31
32 zero-order with respect to 2-aminopyridine. Another mechanistic possibility which has to be taken
33
34 into consideration, is initial formation enamine intermediates in reaction of 2-aminopyridine with
35
36 acetophenone followed by iodination and subsequent cyclization to provide imidazo[1,2-*a*]pyridines.
37
38
39
40
41
42

43 Since our aim was to develop a methodology with the widest possible scope, as a model, we
44
45 chose the reaction between 2-aminopyridine (**1**) and 2-hydroxyacetophenone (**2a**) (the presence of a
46
47 phenolic hydroxyl group makes ketone **2a** prone to iodination under the reaction conditions) (Scheme
48
49 1). An additional reason for the choice of substrates was that the prospective product of this reaction (2-
50
51 (imidazo[1,2-*a*]pyridin-2-yl)phenol (**3a**) had been shown to display ESIPT,^{13,14} which was of interest to
52
53 us. Initially, we performed the model reaction using acetonitrile as a solvent, which led to the formation
54
55 of desired product **3a**, but in only 10 % yield. Since reactions in other solvents did not bring any
56
57
58
59
60


appreciable change (Table 1), we attempted to perform the first step in the neat, which improved the yield of product **3a** considerably (Table 2, entry 1).

Table 1. Results of reactions of 2-aminopyridine (**1**) with 2-hydroxyacetophenone (**2a**) in various solvents^a

Entry	Solvent	Yield (%)
1	MeCN	10
2	Toluene	12
3	CH ₂ Cl ₂	2
4	THF	6

^a All reactions were performed under the following constant conditions: 1st step: 4 h at 110 °C followed by overnight stirring at 70 °C; 2nd step: excess aqueous NaOH (45%), 100 °C, 1 h.

Inspired by these preliminary results, we initiated a systematic study of solvent-free reaction conditions. The experiments were focused on the number of equivalents of 2-aminopyridine (**1**) used (Table 2). For these experiments, the second step (cyclization reaction) was carried out under conditions of excess aqueous alkali to create apparent-zero-order reaction conditions with respect to the aqueous base.



Scheme 1.

Table 2. Optimization of relative quantities of reagents in the reaction of 2-aminopyridine (**1**) with 2-hydroxyacetophenone (**2a**)^a

Entry	Ratio 1:2a	Iodine (equiv. vs. 2a)	Yield (%)
1	1	1	26
2	2	1	53
3	3	1	52
4	2	1.20	55
5	2.3	1.20	57
6	2	1.5	54
7	2	2	53

^a All reactions were performed under the following constant conditions: 1st step: solvent free, 4 h at 110 °C followed by overnight stirring at 70 °C; 2nd step: excess aqueous NaOH (45%), 100 °C, 1 h.

During this study, it was found that the reaction is sensitive to the molar ratio between reagents. It seems that a key requirement of the reaction is a minimum twofold excess of 2-aminopyridine and slight excess of iodine with respect to ketone (Table 2, entries 2-5). Further increases to the amounts of these components did not lead to any increase in the yield of the reaction, but caused difficulties in the isolation and purification of the final product (Table 2, entries 6-7). Under the reaction conditions (110°C) 2-aminopyridine becomes a liquid and dissolves all components of the reaction sufficiently.

These data are in good agreement with the data obtained in kinetic³⁶ and other studies²⁸⁻³⁴ of the Ortoleva-King reaction.

Table 3. Scope of the synthesis of imidazo[1,2-*a*]pyridines directly from acetophenones.

Nc1ccncc1 + R-COCH₃ $\xrightarrow[2. \text{NaOH (45\%, aq.)}]{1. \text{I}_2}$ Rc1cnc2ccncc12

1 **2a-j** **3a-j**

Ketone	R	Imidazo[1,2- <i>a</i>]pyridine	Yield
2a		3a	57%
2b		3b	61%
2c		3c	53%
2d		3d	56%
2e		3e	39%
2f		3f	41%
2g		3g	55%
2h		3h	54%
2i		3i	43%
2j		3j	51%

The optimized procedure (Table 2, entry 5: 1 eq. ketone, 1.20 eq. of iodine, excess (2.3 eq.) 2-


1 aminopyridine) was subsequently used in the preparation of various 2-substituted imidazo[1,2-
2 *a*]pyridines. Acetophenones **2b-2f** with diverse substituents (OMe, Br, OH, NEt₂) were reacted with 2-
3 aminopyridine (**1**) (Table 3). All reactions gave rise to the corresponding 2-substituted imidazo[1,2-
4 *a*]pyridines **3b-3f** in moderate-to-good yields (39-61%). Subsequently, we have shown that this
5 methodology may be the extended to other acetophenones including heterocyclic substrates (**2g-2j**).
6 Imidazo[1,2-*a*]pyridines **3g-3j**, bearing both electron-donating and electron-withdrawing moieties, were
7 obtained in good yields (Table 3).
8
9
10
11
12
13
14
15
16
17

18 To demonstrate the scalability of this process, a multi-gram preparation of imidazo[1,2-*a*]pyridine **3a**
19 was attempted. The reaction of 2-aminopyridine (**1**) with 2-hydroxyacetophenone (**2a**) performed at a 37
20 mmol (5 g) scale (20 times larger than the experiments described in Table 3) furnished 3.94 g of
21 imidazo[1,2-*a*]pyridine **3a** in a very similar yield (51%).
22
23
24
25
26
27

28 The spectral characteristics of imidazo[1,2-*a*]pyridines **3a-3f** were examined and compared to those of
29 imidazo[1,2-*a*]pyridines **3g-3j** (Table 4). Optical measurements were performed in several solvents:
30 toluene (non-polar, aprotic), dichloromethane (moderately polar, aprotic), acetonitrile (polar, aprotic),
31 methanol (polar, protic). The most notable feature of all of the imidazo[1,2-*a*]pyridines is an intense UV
32 absorption band ($\lambda_{\text{abs}} = 320\text{-}360\text{ nm}$) regardless of the substituent at position 2. The absorption maxima
33 shifted hypsochromically with increased solvent polarity (Table 4). The emission spectra of all of the
34 studied compounds that possess a 2-hydroxyphenyl substituent strongly depend on the nature of the
35 solvent. In all aprotic solvents, the emission is very weak ($\Phi_{\text{fl}} = 1\text{-}3\%$ typically) and is situated around
36 560 nm. In polar but aprotic CH₃CN compounds **3a-f** showed both blue and orange fluorescence (Table
37 4). While Stokes shifts in unpolar solvents reach 11000 cm⁻¹, in CH₃CN they are even higher (up to
38 13000 cm⁻¹) mainly due to the hypsochromically shifted absorption. By contrast, the emission spectrum
39 in methanol shows a stronger non-ESIPT emission band in the blue region ($\lambda_{\text{max}} = 370\text{-}390\text{ nm}$, $\Phi_{\text{fl}} = 5\text{-}$
40 17%). Stokes shifts are moderate in MeOH (2500-4600 cm⁻¹). The only exception is compound **3f**,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 which possesses an additional strongly electron-donating Me₂N group at position 4 of the phenyl ring.
2
3 Both absorption and emission of **3f** in MeOH are significantly bathochromically shifted when compared
4
5 with imidazo[1,2-*a*]pyridines **3a-3e** (Table 4). The resulting Stokes shift reaches 6700 cm⁻¹ in this case.
6
7 The dramatic increase in the fluorescence quantum yield of compounds **3a-3f** in MeOH can be
8
9 attributed to the fact that, as reported by Douhal *et al.*,¹³ in hydrogen-bonding media (such as MeOH),
10
11 solvated structures such as **3a_{iii}**, which emit in near-UV/blue-violet region, are favored and consequently
12
13 ES IPT is prevented (Scheme 2). These results indicate that blue fluorescence is due to direct emission
14
15 from a localized excited state, and that orange fluorescence is the ES IPT fluorescence from zwitterionic
16
17 **3a_{ii}**. Interestingly, for dyes **3c** and **3d** containing bromine atom, ES IPT-type emission was also visible in
18
19 MeOH (albeit very weak, Table 4). Emission of the remaining compounds **3g-3j**, which are not capable
20
21 of ES IPT, is not so strongly solvent-dependent. Upon excitation at 330 nm, **3g-3j** show strong blue
22
23 fluorescence at 370-380 nm. Again the exception is imidazo[1,2-*a*]pyridine **3i**, which possesses a
24
25 strongly electron-donating pyrrole moiety. In this case the emission maximum is shifted into the violet
26
27 region (390-410 nm). The nearly identical emission wavelengths for compounds **3a** and **3g** ($\lambda_{\text{max}} = 372$ -
28
29 376 nm) is evidence that their geometries in the excited state are very similar. For non-ES IPT
30
31 imidazo[1,2-*a*]pyridines, the Stokes shift is moderate (~4200 cm⁻¹), except for compound **3i** in polar
32
33 solvents (~5500 cm⁻¹). The notable difference is that Φ_{fl} of dyes **3g-3j** in MeOH is very high (40-80%).
34
35 Of particular interest is the fact that the values of the Stokes shifts are essentially the same for groups of
36
37 compounds regardless of whether they possess the proton donor necessary for ES IPT. Stokes shifts
38
39 lower than 6000-8000 cm⁻¹ can typically be explained based on a “solute-solvent” polarizable
40
41 continuum model of interaction. This “solute-solvent” model of interaction considers only a change in
42
43 the dipole interaction energy of the fluorophore, which is induced by the electric field of the solvent by
44
45 increasing the dipole moment of the fluorophore in the excited state. Thus, a red shift is associated with
46
47 the macroscopic rate of solvent: dielectric constant and refraction index. The optical properties of
48
49 compound **3g-3j** can be explained according to this model. The assumptions applied are in a good
50
51
52
53
54
55
56
57
58
59
60

agreement with data published by Douhal *et al.*¹³



Scheme 2.

Araki and co-workers reported¹⁴ that the ES IPT process, accompanied by a large Stokes shift ($\sim 9700 \text{ cm}^{-1}$) and dependent on the structure of polymorphs, in imidazo[1,2-*a*]pyridines derivatives is strongly visible in the solid state. The idea developed by Acuña and co-workers and presented in Scheme 2 provides a satisfactory explanation of the observed large Stokes shift of the blue-green-yellow emission in the solid state. 2'-Hydroxy derivatives of 2-phenylimidazo[1,2-*a*]pyridine in solid state do not experience solvation effects, allowing them to stay in the zwitterionic ES IPT-active form **3a_{iii}**.^{13,14} We performed solid-state emission measurements for imidazo[1,2-*a*]pyridines **3a-j** (Table 5). Strong fluorescence was observed for ES IPT-capable imidazopyridines **3a-f** ($\lambda_{\text{em}} = 490\text{-}520 \text{ nm}$). The emission maximum for compound **3a** (494 nm) perfectly correlates with properties of polymorph BG described by Araki and co-workers.^{14b} Again, emission maximum is strongly bathochromically shifted for imidazopyridine **3f** (546 nm). Two out of non-ES IPT imidazopyridines also display luminescence in the solid state, however emission is weak and hypsochromically shifted (Table 5).

Table 4. Spectroscopic properties of compounds **3a-3j**

Compo	Solvent	$\lambda_{\text{abs}} /$	ϵ	$\lambda_{\text{em}} /$	Φ_{fl}^a	Stokes shift

und		nm		nm		(cm ⁻¹)
3a	toluene	351	8800	573	0.011	11000
	CH ₂ Cl ₂	345	7900	573	0.005	11500
	CH ₃ CN	328	12100	380	0.006	4200
				577	0.003	13100
	MeOH	328	12000	375	0.084	3800
3b	toluene	340	13900	560	0.036	11500
	CH ₂ Cl ₂	334	14900	572	0.010	12500
	CH ₃ CN	330	15000	385	0.002	4300
				579	0.001	13000
	MeOH	331	15000	385	0.124	4200
3c	toluene	352	10000	561	0.036	10600
	CH ₂ Cl ₂	347	10800	370	0.013	1800
	CH ₃ CN	344	10600	378	0.002	2600
				583	0.003	11900
	MeOH	330	14600	372	0.046	3100
				562	0.002	12200
3d	toluene	351	11800	541	0.087	10000

	CH ₂ Cl ₂	347	12200	541	0.055	10300
	CH ₃ CN	344	11700	379	0.002	2700
				556	0.015	11100
	MeOH	342	11000	374	0.059	2500
				538	0.010	10600
3e	toluene	355	12100	559	0.048	10300
	CH ₂ Cl ₂	351	13400	560	0.019	10600
	CH ₃ CN	331	13300	387	0.004	4400
				583	0.002	13100
	MeOH	332	11900	393	0.168	4700
3f	toluene	361	20300	572	0.034	10200
	CH ₂ Cl ₂	354	22700	579	0.015	11000
	CH ₃ CN	350	23500	455	0.002	6600
				584	0.002	11500
	MeOH	350	22600	458	0.092	6700
3g	toluene	332	8100	381	0.607	3900
	CH ₂ Cl ₂	328	8200	376	0.552	3900
	CH ₃ CN	325	8500	378	0.555	4300

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3h	MeOH	321	8900	374	0.796	4400
	toluene	333	8600	382	0.571	3900
	CH ₂ Cl ₂	330	8400	378	0.515	3900
	CH ₃ CN	328	8500	377	0.525	4000
3i	MeOH	323	9600	374	0.480	4200
	toluene	342	11500	393	0.590	3800
	CH ₂ Cl ₂	355	11600	401	0.427	3200
	CH ₃ CN	333	11000	406	0.544	5400
3j	MeOH	333	11800	410	0.481	5600
	toluene	351	6900	383	0.585	2400
	CH ₂ Cl ₂	333	10600	380	0.660	3700
	CH ₃ CN	331	10500	382	0.644	4000
	MeOH	327	11300	377	0.767	4100

^a Determined in MeOH using quinine sulphate in 0.5 M H₂SO₄ as a standard

Table 5. Solid state emission maxima of compounds **3a-j**.

Compound	$\lambda_{em\ max}$ [nm]
3a	494
3b	520
3c	483

3d	492
3e	503
3f	546
3g	-
3h	-
3i	395
3j	390

Conclusions

In summary, we have developed a new method for the direct preparation of imidazo[1,2-*a*]pyridines from acetophenones and 2-aminopyridine, *via* an Ortoleva-King reaction followed by ring closure. We have demonstrated that the initially-formed pyridinium salts undergo efficient ring-closure in the presence of base. The reaction is functional group tolerant and allows for the preparation of an unprecedented library of derivatives including compounds bearing a strongly electron-donating group at position 2. Imidazo[1,2-*a*]pyridines possessing a 2-hydroxyphenyl substituent at position 2 exhibit ES IPT in the majority of solvents, resulting in weak but highly bathochromically-shifted emission peaks. In MeOH however, ES IPT is prevented by intermolecular hydrogen bonding; as a result, compounds emit in the violet-blue region. Solid state emission maxima follow the same trend as fluorescence in the solution i.e. the presence of strongly electron-donating groups at phenyl ring shift emission from blue-green region to yellow one. Imidazo[1,2-*a*]pyridines possessing aryl substituents at position 2 display strong emission bands in the blue region (fluorescence quantum yields = 0.40-0.80). These results are not only of theoretical significance in that they provide new insight into factors influencing the optical properties of imidazo[1,2-*a*]pyridines, but they may also open the door to practical applications. The use of the described approach can open the way to the synthesis of a wide range of these heterocycles, which can serve as an ideal platform to obtaining more complex systems.

Experimental Section

1
2
3 **General.** All chemicals were used as received unless noted otherwise. Reagent grade solvents
4 (CH₂Cl₂, hexanes) were distilled prior to use. Spectrophotometric grade solvents were used without
5 further purification. All reported ¹H NMR and ¹³C NMR spectra were collected using 500 or 600 MHz
6 spectrometers. Chemical shifts (δ ppm) were determined with TMS as an internal standard; *J* values are
7 given in Hz. The UV/Vis absorption spectra were recorded on a spectrophotometer in toluene, CH₂Cl₂,
8 acetonitrile or methanol. Emission spectra were recorded on a fluorescence spectrophotometer in
9 methanol. Emission spectra are presented in photon units with the extinction coefficient in M⁻¹ cm⁻¹ in
10 brackets, and have been corrected for instrumental factors. Fluorescence quantum yields (Φ_f) were
11 measured with quinine sulphate in 0.5 M H₂SO₄ as a reference and were corrected for the refractive
12 index of the solvent. Melting points were determined using a capillary-type apparatus. Chromatography
13 was performed on silica (230-400 mesh). Dry column vacuum chromatography (DCVC) was performed
14 on preparative thin-layer chromatography alumina. Mass spectra were obtained *via* electron impact
15 mass spectrometry with double focusing sector mass analyzer (EI-MS).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Exemplary procedure for the preparation of imidazo[1,2-*a*]pyridines starting from 2-**
34 **aminopyridine (1). 2-(Imidazo[1,2-*a*]pyridin-2-yl)phenol (3a).** A sealed tube was charged with 1-(2-
35 hydroxyphenyl)ethanone (**2a**) (250 mg, 1.84 mmol), 2-aminopyridine (**1**) (398 mg, 4.23 mmol) and
36 iodine (560 mg, 2.21mmol). The reaction mixture was stirred at 110 °C. After 4 h the mixture was
37 cooled to 70 °C and stirred overnight. The residue was diluted with 5 mL distilled water and an excess
38 of aqueous sodium hydroxide (45%) was added. The reaction mixture was stirred at 100 °C for 1 h.
39 After cooling to room temperature, the reaction mixture was diluted with 25 mL CH₂Cl₂. 10 % aqueous
40 HCl was added to the water-organic mixture until a neutral pH was obtained. The mixture was then
41 extracted with CH₂Cl₂. The organic layer was washed with water, dried over Na₂SO₄ and concentrated
42 under reduced pressure. The solid was isolated by column chromatography (silica, CH₂Cl₂/hexanes 1:2
43 → CH₂Cl₂/hexanes 3:1). The pure product was obtained as a solid after crystallisation from ethanol –
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

water (219 mg, 57 %). Data for **3a**: mp 142-143 °C (lit.^{13a} mp 141-142 °C); ¹H NMR (500 MHz, CDCl₃, δ) 6.79 (t, 1H, *J*=6.6 Hz), 6.84 (t, 1H, *J*=7.4 Hz), 7.02 (d, 1H, *J*=8.2 Hz), 7.17-7.25 (m, 2H), 7.52 (t, 2H, *J*=8.6 Hz), 7.78 (s, 1H), 8.08 (d, 1H *J*=6.6 Hz), 12.81 (broad s, 1H); ¹³C NMR (125 MHz, CDCl₃, δ) 106.9, 113.3, 115.5, 116.4, 116.8, 117.8, 119.1, 125.3, 125.6, 125.7, 125.9, 129.8, 157.5; EI-HR obsd 210.0797, calcd exact mass 210.0793 (C₁₃H₁₀N₂O).

2-(Imidazo[1,2-*a*]pyridin-2-yl)-5-methoxyphenol (3b). Prepared following exemplary procedure from 1-(2-hydroxy-4-methoxyphenyl)ethanone (**2b**) (250 mg, 1.50 mmol), 2-aminopyridine (**1**) (325 mg, 3.46 mmol) and iodine (426 mg, 1.81 mmol). The solid was isolated by column chromatography (silica, CH₂Cl₂/hexanes 1:2 → CH₂Cl₂/hexanes 3:1). The pure product was obtained as a solid after crystallisation from ethanol (220 mg, 61 %). Data for **3b**: mp 153-155 °C; ¹H NMR (500 MHz, CDCl₃, δ) 3.82 (s, 3H), 6.46 (dd, 1H, *J*₁=2.5 Hz, *J*₂=8.6 Hz), 6.58 (d, 1H, *J*=2.5 Hz), 6.81 (t, 1H *J*=6.7 Hz), 7.18 (t, 1H, *J*=7.8 Hz), 7.46 (d, 1H, *J*=8.6 Hz), 7.54 (d, 1H, *J*=9.0 Hz), 7.74 (s, 1H), 8.11 (d, 1H, *J*=6.7), 12.86 (broad s, 1H); ¹³C NMR (125 MHz, CDCl₃, δ) 55.4, 101.9, 105.7, 106.7, 109.5, 113.1, 116.6, 125.0, 125.4, 126.8, 143.5, 145.6, 159.0, 161.2; EI-HR obsd 240.0892, calcd exact mass 240.0899 (C₁₄H₁₂N₂O₂).

4-Bromo-2-(imidazo[1,2-*a*]pyridin-2-yl)phenol (3c). Prepared following exemplary procedure from 1-(5-bromo-2-hydroxyphenyl)ethanone (**2c**) (250 mg, 1.16 mmol), 2-aminopyridine (**1**) (252 mg, 2.67 mmol) and iodine (353 mg, 1.39 mmol). The solid was isolated by column chromatography (silica, CH₂Cl₂/hexanes 1:2 → CH₂Cl₂/hexanes 3:2). The pure product was obtained as a solid (178 mg, 53 %). Data for **3c**: mp 208-209 °C; ¹H NMR (500 MHz, CDCl₃, δ) 6.87-6.92 (m, 2H), 7.24-7.27 (m, 1H), 7.28 (dd, 1H, *J*₁=2.4 Hz, *J*₂=8.8 Hz), 7.58 (d, 1H, *J*=9.0 Hz), 7.68 (d, 1H, *J*=2.4 Hz), 7.84 (s, 1H), 8.15 (d, 1H, *J*=6.7), 12.75 (broad s, 1H); ¹³C NMR (125 MHz, CDCl₃, δ) 107.2, 110.8, 113.6, 117.0, 118.2, 119.7, 125.6, 125.7, 132.3, 143.6, 144.1, 156.6; EI-HR obsd 287.9904, calcd exact mass 287.9898 (C₁₃H₉BrN₂O).

5-Bromo-2-(imidazo[1,2-*a*]pyridin-2-yl)phenol (3d). Prepared following exemplary procedure from

1-*(4-bromo-2-hydroxyphenyl)ethanone* (**2d**) (210 mg, 0.98 mmol), 2-aminopyridine (**1**) (211 mg, 2.25 mmol) and iodine (297 mg, 1.17 mmol). The solid was isolated by column chromatography (silica, CH₂Cl₂/hexanes 1:1 → CH₂Cl₂). The pure product was obtained as a solid (158 mg, 56 %). Data for **3d**: mp 154-155 °C; ¹H NMR (500 MHz, CDCl₃, δ) 6.85 (t, 1H, J=5.9 Hz), 6.97-6.99 (m, 1H), 7.19 (s, 1H), 7.22 (d, 1H, J=7.8 Hz), 7.38 (t, 1H, J=7.0 Hz), 7.55 (dd, 1h, J₁=2.7 Hz, J₂=8.7 Hz), 7.8 (d, 1H, J=6.3 Hz), 8.12 (t, 1H, J=5.0 Hz), 12.94 (broad s, 1H); ¹³C NMR (125 MHz, CDCl₃, δ) 106.9, 113.5, 115.4, 116.9, 120.9, 122.3, 122.7, 125.6, 126.8, 126.9, 143.5, 144.6, 158.3; EI-HR obsd 287.9890, calcd exact mass 287.9898 (C₁₃H₉BrN₂O).

4-(Imidazo[1,2-*a*]pyridin-2-yl)benzene-1,3-diol (**3e**). Prepared following exemplary procedure from 1-(2,4-dihydroxyphenyl)ethanone (**2e**) (150 mg, 0.99 mmol), 2-aminopyridine (**1**) (213 mg, 2.27 mmol) and iodine (300 mg, 1.18 mmol). The solid was isolated by column chromatography (silica, CH₂Cl₂/ethyl acetate 1:1). The pure product was obtained as a solid (87 mg, 39 %). Data for **3e**: mp 114-115 °C (lit.³⁷ mp 115 °C); ¹H NMR (500 MHz, DMSO-d₆, δ) 6.33 (d, 2H, J=11.6 Hz), 6.94 (t, 1H, J=6.4 Hz), 7.28 (t, 1H, J=7.6 Hz), 7.60-7.64 (m, 1H), 8.28 (s, 1H), 8.56 (d, 1H, J=6.4 Hz), 9.52 (s, 1H), 12.09 (broad s, 2H); ¹³C NMR (125 MHz, DMSO-d₆, δ) 103.4, 107.7, 107.9, 109.1, 113.2, 115.9, 125.8, 127.1, 127.9, 143.2, 144.2, 158.1, 159.1; EI-HR obsd 226.0739, calcd exact mass 226.0742 (C₁₃H₁₀N₂O₂).

5-(Diethylamino)-2-(imidazo[1,2-*a*]pyridin-2-yl)phenol (**3f**). Prepared following exemplary procedure from 1-(4-(diethylamino)-2-hydroxyphenyl)ethanone (**2f**) (250 mg, 1.21 mmol), 2-aminopyridine (**1**) (261 mg, 2.77 mmol) and iodine (367 mg, 1.45 mmol). The solid was isolated by column chromatography (silica, ethyl acetate/CH₂Cl₂ 3:2). The pure product was obtained as a solid (139 mg, 41 %). Data for **3f**: mp 167-169 °C; ¹H NMR (500 MHz, DMSO-d₆, δ) 1.09 (t, 6H, 6.8 Hz), 3.34 (d, 4H, J=6.5 Hz), 6.14 (s, 1H), 6.25 (d, 1H, J=8.5 Hz), 6.92 (t, 1H, J=6.6 Hz), 7.26 (t, 1H, J=7.8 Hz), 7.54 (dd, 2H J₁=8.8 Hz, J₂=15.5 Hz), 8.22 (s, 1H), 8.53 (d, 1H, J=6.6 Hz), 12.04 (broad s, 1H); ¹³C NMR (125 MHz, DMSO-d₆, δ) 12.6, 43.7, 98.5, 103.6, 104.6, 106.4, 125.1, 126.4, 127.3, 142.8, 144.6,

148.6, 157.8; EI-HR obsd 281.1536, calcd exact mass 281.1528 (C₁₇H₁₉N₃O).

2-Phenyl-imidazo[1,2-*a*]pyridine (3g). Prepared following exemplary procedure from acetophenone (**2g**) (500 mg, 4.16 mmol), 2-aminopyridine (**1**) (901 mg, 9.57 mmol) and iodine (1268 mg, 5.00 mmol). The solid was chromatographed by DCVC (alumina, CH₂Cl₂/hexanes 1:2 → CH₂Cl₂). The pure product was obtained as a solid (445 mg, 55%). Data for **3g**: mp 133-134 °C (lit.¹⁸ mp 134 °C); ¹H NMR (500 MHz, CDCl₃, δ) 6.75 (t, 1H, J=6.6 Hz), 7.15 (t, 1H, J=7.8 Hz), 7.32 (t, 1H, J=7.3 Hz), 7.42 (t, 2H, J=7.6 Hz), 7.62 (d, 1H, J=9.0), 7.86 (s, 1H), 7.95 (d, 2H, J=7.3 Hz), 8.10 (d, 1H, J=6.7 Hz); ¹³C NMR (125 MHz, CDCl₃, δ) 108.1, 112.4, 117.6, 124.57, 124.64, 125.6, 126.1, 128.0, 128.7, 133.8, 145.7, 145.9; EI-HR obsd 194.0836, calcd exact mass 194.0844 (C₁₃H₁₀N₂).

2-(Pyridin-2-yl)-imidazo[1,2-*a*]pyridine (3h). Prepared following exemplary procedure from 1-(pyridin-2-yl)ethanone (**2h**) (250 mg, 2.06 mmol), 2-aminopyridine (**1**) (447 mg, 4.75 mmol) and iodine (629 mg, 2.48 mmol). The solid was chromatographed by DCVC (alumina, CH₂Cl₂/hexanes 1:1 → CH₂Cl₂). The pure product was obtained as a solid (217 mg, 54%). Data for **3h**: mp 139-140 °C; ¹H NMR (500 MHz, DMSO-*d*₆, δ) 6.90 (t, 1H, J=6.7 Hz), 7.25 (t, 1H, J=7.8 Hz), 7.30 (t, 1H, J=5.9 Hz), 7.60 (d, 1H, J=8.8 Hz), 7.86 (t, 1H, J=7.5 Hz), 8.11 (d, 1H, J=7.8 Hz), 8.49 (s, 1H), 8.57-8.60 (m, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆, δ) 111.3, 113.5, 117.0, 119.8, 122.7, 125.3, 127.2, 137.0, 144.7, 144.8, 149.4, 152.8; EI-HR obsd 195.0789, calcd exact mass 195.0797 (C₁₂H₉N₃).

2-(Pyrrol-2-yl)-imidazo[1,2-*a*]pyridine (3i). Prepared following exemplary procedure from 1-(pyrrol-2-yl)ethanone (**2i**) (150 mg, 1.37 mmol), 2-aminopyridine (**1**) (298 mg, 3.16 mmol) and iodine (419 mg, 1.65 mmol). The solid was isolated by column chromatography (silica, CH₂Cl₂/ethyl acetate 5:1 → CH₂Cl₂/ethyl acetate 1:1). The pure product was obtained as a solid (108 mg, 43 %). Data for **3i**: mp 198-199 °C; ¹H NMR (500 MHz, DMSO-*d*₆, δ) 6.10 (d, 1H, J=2.6 Hz), 6.48 (s, 1H), 6.79 (s, 1H), 6.82 (t, 1H J=6.7 Hz), 7.17 (t, 1H, J=7.48 Hz), 7.47 (d, 1H, J=9.00 Hz), 8.04 (s, 1H), 8.50 (d, 1H, J=6.65 Hz), 11.32 (s, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆, δ) 105.9, 106.5, 108.6, 111.8, 115.8, 118.6, 124.3, 126.3, 126.6, 139.6, 144.4; EI-HR obsd 183.0796, calcd exact mass 183.0797 (C₁₁H₉N₃).

1 **2-(Thiophen-2-yl)-imidazo[1,2-*a*]pyridine (3j)**. Prepared following exemplary procedure from 1-
2 (thiophen-2-yl)ethanone (**2j**) (250 mg, 1.98 mmol), 2-aminopyridine (**1**) (429 mg, 4.56 mmol) and
3 iodine (603 mg, 2.38 mmol). The solid was chromatographed by DCVC (alumina, CH₂Cl₂/hexane 1:1 →
4 CH₂Cl₂). The pure product was obtained as a solid (202 mg, 51 %). Data for **3j**: mp 151-153 °C (lit.³⁸
5 mp 137-138 °C); ¹H NMR (500 MHz, CDCl₃, δ) 6.75 (t, 1H, J=6.7 Hz), 7.08 (dd, 1H, J₁=3.7 Hz, J₂=4.9
6 Hz), 7.14 (t, 1H, J=7.9 Hz), 7.30 (d, 1H, 5.0 Hz), 7.47 (d, 1H, J=3.5 Hz), 7.60 (d, 1H, J=9.0 Hz), 7.76 (s,
7 1H), 8.06 (d, 1H, 6.7 Hz); ¹³C NMR (125 MHz, CDCl₃, δ) 107.6, 112.7, 117.5, 123.8, 124.9, 125.2,
8 125.6, 127.9, 137.7, 141.0, 145.6; EI-HR obsd 200.0403, calcd exact mass 200.0408 (C₁₁H₈N₂S).

9
10
11
12
13
14
15
16
17
18
19 **Multi-gram scale preparation of 2-(imidazo[1,2-*a*]pyridin-2-yl)phenol (3a)**. A sealed tube was
20 charged with 1-(2-hydroxyphenyl)ethanone (**2a**) (5.000 g, 36.72 mmol), 2-aminopyridine (**1**) (7.948 g,
21 84.47 mmol) and iodine (11.183 g, 44.06 mmol). After cooling to room temperature, the reaction
22 mixture was diluted with 25 mL CH₂Cl₂. 10 % aqueous HCl was added to the water-organic mixture
23 until a neutral pH was obtained. The mixture was then extracted with CH₂Cl₂. The organic layer was
24 washed with water, dried over Na₂SO₄ and concentrated under reduced pressure. The solid was isolated
25 by column chromatography (silica, CH₂Cl₂/hexanes 1:2 → CH₂Cl₂/hexanes 3:1). The pure product was
26 obtained as a solid (3.937 g, 51 %).
27
28
29
30
31
32
33
34
35
36
37
38

39 **Acknowledgement:** A. J. S., M. K. C. and D.T. G. gratefully acknowledge the Foundation for Polish
40 Science for supporting this work under MPD/2010/4 project "Towards Advanced Functional Materials
41 and Novel Devices - Joint UW and WUT International PhD Programme". We thank Heather Buckley
42 (UC Berkeley) for amending the manuscript.
43
44
45
46
47
48

49 **Supporting Information Available:** ¹H NMR and ¹³C NMR spectra of compounds **3a-3j**. This material
50 is available free of charge via the Internet at <http://pubs.acs.org>.
51
52

53 REFERENCES

- 54
55
56
57 (1) Tschitschibabin, A. E. *Chem.. Ber.* **1925**, 58, 1705.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (2) (a) Elhakmaoui, A.; Gueiffier, A.; Milhavet, J.-C.; Blache, Y.; Chapat, J.-P.; Chavignon, O.; Teulade, J.-C.; Snoeck, R.; Andrei, G.; De Clercq, E. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 1937. (b) Townsend, L. B.; Drach, J. C. *WO9727205*. (c) Mavel, S.; Renou, J. L.; Galtier, C.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E.; Gueiffier, A. *Arzneim.-Forsch.* **2001**, *51*, 304.
- (3) (a) Lacerda, R. B.; De Lima, C. K.; Da Silva, L. L. *Bioorg. Med. Chem. Lett.* **2009**, *17*, 74. (b) Abignente, E. *Actual. Chim. Ther.* **1991**, *18*, 193; *Chem. Abstr.* **1991**, *115*, 256028n.
- (4) (a) Abignente, E.; Arena, F.; Luraschi, E.; Saturnino, C.; Rossi, F.; Lampa, E.; Cazzola, M.; Brandinelli, E.; Marrazzo, R.; Marmo, E. *Rend. Atti. Accad. Sci. Med. Chir.* **1985**, *139*, 313. (b) Almirante, L.; Polo, L.; Mugnaini, A.; Provinciali, E.; Rugarli, P.; Biancotti, A.; Gamba, A.; Murmann, W. *J. Med. Chem.* **1965**, *8*, 305.
- (5) Teulade, J. C.; Grassy, G.; Girard, J. P.; Chapat, J. P. *Eur. J. Med. Chem.* **1978**, *13*, 271.
- (6) Byth, K. F.; Culshaw, J. D.; Green, S.; Oakes, S.; Thomaset, A. P. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2245.
- (7) Fuchs, K.; Romig, M.; Mendla, K.; Briem, H.; Fechteler, K. *WO2002014313*; *Chem. Abstr.* **2002**, *136*, 183824r.
- (8) (a) Humphries, A. C.; Gancia, E.; Gilligan, M. T.; Goodacre, S.; Hallett, D.; Marchant, K. J.; Thomas, S. R. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1518. (b) Fookes, C. J. R.; Pham, T. Q.; Mattner, F.; Greguric, I.; Loc'h, C.; Liu, X.; Berghofer, P.; Shepherd, R.; Gregoire M.-C.; Katsifis A. *J. Med. Chem.* **2008**, *51*, 3700.
- (9) Dvey, D.; Erhardt, P. W.; Lumma, W. C. Jr.; Wiggins, J.; Sullivan, M.; Pang, D.; Cantor, E. *J. Med. Chem.* **1987**, *30*, 1337.
- (10) Langer, S. Z.; Arbilla, S.; Benavides, J. *Adv. Biochem. Psychopharmacol.* **1990**, *46*, 61.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (11) Harrison, T. S.; Keating, G. M. *CNS Drugs*, **2005**, *19*, 65.
- (12) Ueda, T.; Mizusgige, K.; Yukiiri, K.; Takahashi, T. *Cerebrovasc. Dis.* **2003**, *16*, 396.
- (13) (a) Douhal, A.; Amat-Guerri, F.; Acuña, A. U. *J. Phys. Chem.* **1995**, *99*, 76. (b) Douhal, A.; Amat-Guerri, F.; Acuña, A. U. *Angew. Chem., Int. Ed.* **1997**, *36*, 1514. (c) Douhal, A. *Ber. Bunsen Ges. Phys. Chem.* **1998**, *102*, 448.
- (14) (a) Shono, H.; Ohkava, T.; Tomoda, H.; Mutai, T.; Araki, K. *ACS Appl. Mater. Interfaces* **2011**, *3*, 654. (b) Mutai, T.; Tomoda, H.; Ohkawa, T.; Yabe, Y.; Araki, K. *Angew. Chem., Int. Ed.* **2008**, *47*, 9522. (c) Tomoda, H.; Hirano, T.; Saito, S.; Mutai, T.; Araki, K. *Bull. Chem. Soc. Jpn.* **1999**, *72*, 1327.
- (15) (a) Kwon, J. E.; Park, S.Y. *Adv. Mat.* **2011**, *23*, 3615-3642. (b) G.-J. Zhao, K.-L. Han, *Accounts Chem. Res.* **2012**, *45*, 404. (c) Fang, C.; Frontiera, R. R.; Tran, R.; Mathies, R. A.; *Nature* **2009**, *462*, 200-204. (d) Klymchenko, A. S.; Demchenko, A. P. *Phys. Chem. Chem. Phys.* **2004**, *5*, 461. (e) Das, K.; Sarkar, N.; Ghosh, A. K.; Majumdar, D.; Nath, D. N.; Bhattacharyya, K. *J. Phys. Chem.* **1994**, *98*, 9126. (f) Lochbrunner, S.; Wurzer, A. J.; Riedle, E. *J. Chem. Phys.* **2000**, *112*, 10699. (g) Henary, M. M.; Fahrni, C. J. *J. Phys. Chem. A* **2002**, *106*, 5210. (h) Chou, P.-T.; Chen, Y.-C.; Yu, W.-S.; Chou, Y.-H.; Wei, C.-Y.; Cheng, Y.-M. *J. Phys. Chem. A* **2001**, *105*, 1731. (i) Piechowska, J.; Gryko, D. T. *J. Org. Chem.* **2011**, *76*, 10220. (j) Iijima, T.; Momotake, A.; Shinohara, Y.; Sato, T.; Nishimura, Y.; Arai, T. *J. Phys. Chem. A* **2010**, *114*, 1603. (k) Deperasińska, I.; Gryko, D. T.; Karpiuk, E.; Kozankiewicz, B.; Makarewicz, A.; Piechowska J., *J. Phys. Chem. A* **2012**, *116*, 2109. (l) Catalan, J.; Fabero, F.; Guijarro, M. S.; Claramunt, R. M.; Santa Maria, M. D.; De La Concepcion Foces-Foces, M.; Hernandez Cano, F.; Elguero, J.; Sastre, R. *J. Am. Chem. Soc.* **1990**, *112*, 747. (m) Lim, S.-J.; Seo, J.; Park, S.Y. *J. Am. Chem. Soc.* **2006**, *128*, 14542.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (16) (a) Shynkar, V. V.; Klymchenko, A. S.; Kunzelmann, C.; Duportail, G.; Muller, C. D.; Demchenko, A. P.; Freyssinet, J.-M.; Mely, Y. *J. Am. Chem. Soc.* **2007**, *129*, 2187. (b) Maliakal, A.; Lem, G.; Turro, N. J.; Ravichandran, R.; Suhadolnik, J. C.; DeBellis, A. D.; Wood, M. G.; Lau, J. *J. Phys. Chem. A* **2004**, *106*, 7680. (c) Morales, A. R.; Schafer-Hales, K. J.; Yanez, C. O.; Bondar, M. V.; Przhonska, O. V.; Marcus, A. I.; Belfield, K. D. *ChemPhysChem* **2009**, *10*, 2073.
- (17) (a) Henary, M. M.; Wu, Y.; Fahrni, C. *J. Chem. – Eur. J.* **2004**, *10*, 3015. (b) Wu, Y.; Peng, X.; Fan, J.; Gao, S.; Tian, M.; Zhao, J.; Sun, S. *J. Org. Chem.* **2007**, *72*, 62. (c) Shynkar, V. V.; Klymchenko, A. S.; Piémont, E.; Demchenko, A. P.; Mély, Y. *J. Phys. Chem. A* **2004**, *108*, 8151. (d) Mintova, S.; De Waele, V.; Schmidhammer, U.; Riedle, E.; Bein, T. *Angew. Chem., Int. Ed.* **2003**, *42*, 1611.
- (18) (a) Rode M. F.; Sobolewski, A. L. *J. Phys. Chem. A*, **2010**, *114*, 11879. (b) Mitra, S.; Mukherjee, S. *J. Lumin.* **2006**, *118*, 1. (c) Lim, S.-J.; Seo, J.; Park, S. Y. *J. Am. Chem. Soc.* **2006**, *128*, 14542.
- (19) (a) Gueiffier, A.; Lhassani, M.; Elhakmaoui, A.; Snoeck, R.; Andrei, G.; Chavignon, O.; Teulade, J.-C.; Kerbal, A.; Essassi, E. M.; Debouzy, J.-C.; Witvrouw, M.; Blache, Y.; Balzarini, J.; De Clercq, E.; Chapat, J.-P. *J. Med. Chem.* **1996**, *39*, 2856. (b) Gueiffier, A.; Mavel, S.; Lhassani, M.; Elhakmaoui, A.; Snoeck, R.; Andrei, G.; Chavignon, O.; Teulade, J.-C.; Witvrouw, M.; Balzarini, J.; De Clercq, E.; Chapat, J.-P. *J. Med. Chem.* **1998**, *41*, 5108. (c) Hand, E. S.; Paudler, W. W. *J. Org. Chem.* **1978**, *43*, 2900.
- (20) (a) DiMauro, E. F.; Kennedy, J. M. *J. Org. Chem.* **2007**, *72*, 1013. (b) Groebke, K.; Weber, L.; Mehlin, F. *Synlett* **1998**, 661. (c) Adib, M.; Sheikhi, E.; Rezaei, N. *Tetrahedron Lett.* **2011**, *52*, 3191.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (21) (a) Chernyak, N.; Gevorgyan, V. *Angew. Chem. Int. Ed.* **2010**, *49*, 2743. (b) Mishra, S.; Ghosh, R.; *Synthesis* **2011**, 3463. (c) Reddy, B. V. S.; Reddy, P. S.; Reddy, Y. J.; Yadav J.S. *Tetrahedron Lett.* **2011**, *52*, 5789. (d) Liu, P.; Fang, L.-S.; Lei, X.; Lin, G.-Q. *Tetrahedron Lett.* **2010**, *51*, 4605.
- (22) Shao, N.; Pang, G.-X.; Yan, C.-X.; Shi, G.-F.; Cheng, Y. *J. Org. Chem.* **2011**, *76*, 7458.
- (23) Katritzky, A. R.; Xu, Y.-J.; Tu, H. *J. Org. Chem.* **2003**, *68*, 4935.
- (24) Krölker, H.-J.; Hitzemann, R.; Boese, R. *Chem. Ber.* **1990**, *123*, 327.
- (25) Kiselyov, A. S. *Tetrahedron Lett.* **2006**, *47*, 2941.
- (26) Hubert, A. J.; Reimlinger, H. *Chem. Ber.* **1970**, *103*, 3811.
- (27) (a) Aginagalde, M.; Vara, Y.; Arrieta, A.; Zangi, R.; Cebolla, V. L.; Delgado-Camón, A.; Cossío, F. P. *J. Org. Chem.*, **2010**, *75*, 2776. (b) Yan, R.-L.; Yan, H. Ma, C.; Ren, Z.-Y.; Gao, X.-A.; Huang, G.-S.; Liang, Y.-M. *J. Org. Chem.* **2012**, *77*, 2024. (c) Cao, H.; Zhan, H.; Lin, Y.; Lin, X.; Du, Z.; Jiang, H. *Org. Lett.* **2012**, *14*, 1688.
- (28) Ortoleva, G. *Gazz. Chim. Ital.* **1899**, *29*, 503.
- (29) (a) King, L. C. *J. Am. Chem. Soc.* **1944**, *66*, 894. (b) King, L. C.; McWhirter, M.; Rowland, R. *J. Am. Chem. Soc.* **1948**, *70*, 239. (c) King, L. C. *J. Am. Chem. Soc.* **1948**, *70*, 242.
- (30) Kröhnke, F. *Angew. Chem., Int. Ed.* **1963**, *2*, 225.
- (31) King, L. C.; McWhirter, M. *J. Am. Chem. Soc.* **1946**, *68*, 717.
- (32) King, L. C.; Abramo, S. V. *J. Org. Chem.* **1958**, *23*, 1609.
- (33) Sapper, D. I.; Southwick, P.L. *J. Org. Chem.* **1956**, *21*, 105.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (34) Jovanovic, M. V. *Heterocycles* **1984**, *22*, 1195.
- (35) Ried, W.; Bender, H. *Chem. Ber.* **1956**, *89*, 1893.
- (36) Pearson, R. G. *J. Am. Chem. Soc.* **1947**, *69*, 3100.
- (37) Kalitaka, B.B.; Hilya, B.P.; Proshakova E.B. *Ukrainskii Khimicheskii Zhurnal* **1988**, *54*, 199.
- (38) Katritzky, A. R.; Qiu, G.; Long, Qiu-He; He, Hai-Ying; Steel, P. J. *J. Org. Chem.* **2000**, *65*, 9201.

SYNOPSIS TOC.

